These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 28970592)

  • 21. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
    Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
    Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypercholesterolemia Induced by a PCSK9 Gain-of-Function Mutation Augments Angiotensin II-Induced Abdominal Aortic Aneurysms in C57BL/6 Mice-Brief Report.
    Lu H; Howatt DA; Balakrishnan A; Graham MJ; Mullick AE; Daugherty A
    Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1753-7. PubMed ID: 27470509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.
    Rashid S; Curtis DE; Garuti R; Anderson NN; Bashmakov Y; Ho YK; Hammer RE; Moon YA; Horton JD
    Proc Natl Acad Sci U S A; 2005 Apr; 102(15):5374-9. PubMed ID: 15805190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-Native Conformational Isomers of the Catalytic Domain of PCSK9 Induce an Immune Response, Reduce Lipids and Increase LDL Receptor Levels.
    Jiang C; Nischal H; Sun H; Li L; Cao Y; Wei P; Chang JY; Teng BB
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29495280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulation of the proprotein convertase subtilisin/kexin type 9 in intestinal epithelial cells.
    Leblond F; Seidah NG; Précourt LP; Delvin E; Dominguez M; Levy E
    Am J Physiol Gastrointest Liver Physiol; 2009 Apr; 296(4):G805-15. PubMed ID: 19179626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced pro-protein convertase subtilisin/kexin type 9 expression by C-reactive protein through p38MAPK-HNF1α pathway in HepG2 cells.
    Cui CJ; Li S; Zhu CG; Sun J; Du Y; Zhang Y; Wu NQ; Guo YL; Xu RX; Gao Y; Li JJ
    J Cell Mol Med; 2016 Dec; 20(12):2374-2383. PubMed ID: 27633999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impacts of ezetimibe on PCSK9 in rats: study on the expression in different organs and the potential mechanisms.
    Xu RX; Liu J; Li XL; Li S; Zhang Y; Jia YJ; Sun J; Li JJ
    J Transl Med; 2015 Mar; 13():87. PubMed ID: 25889684
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis.
    Momtazi-Borojeni AA; Jaafari MR; Badiee A; Banach M; Sahebkar A
    BMC Med; 2019 Dec; 17(1):223. PubMed ID: 31818299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thyroid stimulating hormone exhibits the impact on LDLR/LDL-c via up-regulating hepatic PCSK9 expression.
    Gong Y; Ma Y; Ye Z; Fu Z; Yang P; Gao B; Guo W; Hu D; Ye J; Ma S; Zhang F; Zhou L; Xu X; Li Z; Yang T; Zhou H
    Metabolism; 2017 Nov; 76():32-41. PubMed ID: 28987238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Welsh onion extract inhibits PCSK9 expression contributing to the maintenance of the LDLR level under lipid depletion conditions of HepG2 cells.
    Choi HK; Hwang JT; Nam TG; Kim SH; Min DK; Park SW; Chung MY
    Food Funct; 2017 Dec; 8(12):4582-4591. PubMed ID: 29130084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates.
    Liang H; Chaparro-Riggers J; Strop P; Geng T; Sutton JE; Tsai D; Bai L; Abdiche Y; Dilley J; Yu J; Wu S; Chin SM; Lee NA; Rossi A; Lin JC; Rajpal A; Pons J; Shelton DL
    J Pharmacol Exp Ther; 2012 Feb; 340(2):228-36. PubMed ID: 22019884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of Proprotein Convertase Subtilisin/Kexin Type 9 Ameliorates Liver Fibrosis via Mitigation of Intestinal Endotoxemia.
    Zou Y; Li S; Xu B; Guo H; Zhang S; Cai Y
    Inflammation; 2020 Feb; 43(1):251-263. PubMed ID: 31776890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid Lowering Therapy and Circulating PCSK9 Concentration.
    Nozue T
    J Atheroscler Thromb; 2017 Sep; 24(9):895-907. PubMed ID: 28804094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice.
    Landlinger C; Pouwer MG; Juno C; van der Hoorn JWA; Pieterman EJ; Jukema JW; Staffler G; Princen HMG; Galabova G
    Eur Heart J; 2017 Aug; 38(32):2499-2507. PubMed ID: 28637178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.
    Maxwell KN; Breslow JL
    Proc Natl Acad Sci U S A; 2004 May; 101(18):7100-5. PubMed ID: 15118091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
    Thedrez A; Sjouke B; Passard M; Prampart-Fauvet S; Guédon A; Croyal M; Dallinga-Thie G; Peter J; Blom D; Ciccarese M; Cefalù AB; Pisciotta L; Santos RD; Averna M; Raal F; Pintus P; Cossu M; Hovingh K; Lambert G
    Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1647-50. PubMed ID: 27079874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PCSK9 is Expressed in Human Visceral Adipose Tissue and Regulated by Insulin and Cardiac Natriuretic Peptides.
    Bordicchia M; Spannella F; Ferretti G; Bacchetti T; Vignini A; Di Pentima C; Mazzanti L; Sarzani R
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30634533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.
    Lambert G; Petrides F; Chatelais M; Blom DJ; Choque B; Tabet F; Wong G; Rye KA; Hooper AJ; Burnett JR; Barter PJ; Marais AD
    J Am Coll Cardiol; 2014 Jun; 63(22):2365-73. PubMed ID: 24632287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proprotein convertase subtilisin/kexin type 9 expression is transiently up-regulated in the acute period of myocardial infarction in rat.
    Zhang Y; Liu J; Li S; Xu RX; Sun J; Tang Y; Li JJ
    BMC Cardiovasc Disord; 2014 Dec; 14():192. PubMed ID: 25519174
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia.
    Ohta N; Hori M; Takahashi A; Ogura M; Makino H; Tamanaha T; Fujiyama H; Miyamoto Y; Harada-Shiba M
    J Clin Lipidol; 2016; 10(3):547-555.e5. PubMed ID: 27206942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.